Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Completed

Conditions studied: Gastroenteropancreatic Neuroendocrine Tumor

In brief

An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.

Key facts

Study ID

NCT03017690

Run by

Ipsen

People needed

22

Starts

2017-04-12

Expected to finish

2018-05-30

Last updated by the study team

2018-12-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women must be 18 years of age or older
• A current diagnosis of advanced, unresectable GEP-NET
• Provided written informed consent to participate in the study
• Currently receiving lanreotide or octreotide LAR and has received at least one prior injection of current somatostatin analogues (SSA).

You may not qualify if…

• Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial
• Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate more than 1 injection on the same day
• Scheduled to receive any other treatment in the infusion center/room on the same day and as part of the same appointment
• Known hypersensitivity to somatostatin analogues

Where it is running

• The University of Arizona Cancer Center — Tucson, Arizona, United States
• Ochsner Medical Center Kenner — Kenner, Louisiana, United States
• Mercy Medical Center — Baltimore, Maryland, United States
• National Translational Research Group — East Setauket, New York, United States
• Oncology Specialists of Charlotte — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.